Stock HOWL WEREWOLF THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
6.66 USD -1.33% Intraday chart for Werewolf Therapeutics, Inc. +9.36% +72.54%
Apr. 23 Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting CI
Apr. 05 Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics CI

Business Summary

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Number of employees: 47

Sales per Business

USD in Million2022Weight2023Weight Delta
Cancer Therapeutics
100.0 %
16 100.0 % 20 100.0 % +21.60%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
16 100.0 % 20 100.0 % +21.60%

Managers

Managers TitleAgeSince
Dan Hicklin FOU
 Founder 60 17-10-18
Luke Evnin FOU
 Founder 60 17-10-18
Timothy Trost DFI
 Director of Finance/CFO 66 21-02-07
Chulani Karunatilake CTO
 Chief Tech/Sci/R&D Officer - 21-06-14
Randi Isaacs CTO
 Chief Tech/Sci/R&D Officer 68 20-10-31
Ellen Lubman IRC
 Investor Relations Contact 48 20-07-31

Members of the board

Members of the board TitleAgeSince
Luke Evnin FOU
 Founder 60 17-10-18
Dan Hicklin FOU
 Founder 60 17-10-18
Michael Sherman BRD
 Director/Board Member 58 21-05-26
Briggs Morrison BRD
 Director/Board Member 65 19-10-31
Alon Lazarus BRD
 Director/Board Member 49 19-07-31
Derek DiRocco BRD
 Director/Board Member 43 20-11-30
Michael B. Atkins BRD
 Director/Board Member - Jan. 03
Meeta Chatterjee BRD
 Director/Board Member 69 21-10-27

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 43,347,363 40,623,740 ( 93.72 %) 0 93.72 %

Shareholders

NameEquities%Valuation
MPM BioImpact, Inc
15.61 %
6,672,183 15.61 % 43 M $
RA Capital Management LP
14.38 %
6,144,881 14.38 % 40 M $
RA Capital Management LP
14.38 %
6,144,881 14.38 % 40 M $
PFM Health Sciences LP
8.115 %
3,468,177 8.115 % 22 M $
Adage Capital Partners GP LLC
7.100 %
3,034,255 7.100 % 20 M $
Bank of America, NA (Charlotte, North Carolina)
4.905 %
2,096,081 4.905 % 14 M $
Taiho Ventures LLC
4.841 %
2,068,909 4.841 % 13 M $
Arkin Bio Ventures
4.789 %
2,046,634 4.789 % 13 M $
Rubric Capital Management LP
4.529 %
1,935,357 4.529 % 13 M $
Longwood Fund Management LLC
3.924 %
1,677,082 3.924 % 11 M $

Company contact information

Werewolf Therapeutics, Inc.

200 Talcott Avenue 2nd floor

02472, Watertown

+

http://www.werewolftx.com
address Werewolf Therapeutics, Inc.(HOWL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Werewolf Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.66 USD
Average target price
12.5 USD
Spread / Average Target
+87.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
WEREWOLF THERAPEUTICS, INC. Stock Werewolf Therapeutics, Inc.
+72.54% 293M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. HOWL Stock
  4. Company Werewolf Therapeutics, Inc.